Extended Data Fig. 9: Pro-senescence treatment combined with an mTOR inhibitor suppresses tumour growth in liver cancer xenografts.
From: Inducing and exploiting vulnerabilities for the treatment of liver cancer
a, Representative images of γH2AX and SA-β-gal staining performed on formalin-fixed, paraffin-embedded or frozen sections from subcutaneous Huh7-tumour xenografts treated with vehicle, XL413, AZD8055 or combination of both for 12 days. b, Representative images of SA-β-gal staining performed on frozen sections from subcutaneous SK-Hep1-tumour xenografts treated either with vehicle or with XL413 for 21 days. c, Tumour-volume measurements in mice bearing Huh7- and MHCC97H-tumour xenografts, treated with vehicle, XL413, AZD8055 or a combination of both, at endpoint (12 days for Huh7 and 22 days for MHCC97H). For sample sizes, see Fig. 4a. One mouse in the vehicle group and one mouse in the XL413 group were excluded from the analysis, because the maximum permitted tumour volumes (2,000 mm3) were reached in these mice before the endpoint of the trial. Graph shows mean ± s.e.m., analysed with two-sided unpaired Student’s t-test. d, e, Longitudinal progression of tumour volume in mice bearing Huh7 and MHCC97H tumours, treated with vehicle or sorafenib for 16 or 22 days; this revealed that sorafenib therapy has limited efficacy in these two xenograft models. Graph shows mean ± s.e.m. f, g, Representative images of haematoxylin and eosin (H & E), PCNA, cleaved caspase-3 and phosphorylated 4EBP1 staining performed on formalin-fixed, paraffin-embedded Huh7 and MHCC97H xenografts from mice killed after the last dose of vehicle, XL413, AZD8055 or a combination of both drugs. Data in a, b, f, g are representative of three independent biological experiments.
